Existing laws, built around separate technologies, struggle to pace with integrated computational-biological design, creating gaps and ambiguities in regulation.

Biotechnology and AI are converging rapidly, enabling AI-assisted design of viruses and advanced gene-editing, which is reshaping regulation across multiple jurisdictions.

A core governance challenge is keeping regulatory categories flexible enough to adapt to evolving technologies, balancing the benefits of useful research with the management of anticipated risks without throttling innovation.

New Zealand is proposing a flexible Gene Technology framework that exempts lower-risk gene-editing while subjecting higher-risk activities to controls, signaling an innovation-friendly shift in governance.

The European Union is moving away from rigid classifications toward a tiered oversight system that eases compliance for lower-risk technologies while maintaining strict rules for more complex, higher-risk activities.

Regulatory approaches vary internationally: Australia employs a gene-technology framework with a dedicated regulator and product-specific oversight, whereas the United States relies on a Coordinated Framework that assigns agency responsibilities across federal bodies.

AI-assisted design of bacteriophages, CRISPR therapies, and environmental applications show promise against antibiotic resistance but also carry unpredictable risks and potential for misuse.